Peptide Blog
Articles, dosing guides, and expert insights on peptides and their real-world applications.
Eli Lilly Retatrutide Early Access: Who Qualifies and How (2026)
Eli Lilly retatrutide early access is real but narrow: BMI 35+, top-dose failure, 2+ serious complications. Exact criteria, how doctors apply, cost, odds.
Retatrutide TRIUMPH-2 Results: 20.8% Weight Loss in Type 2 Diabetes
Full retatrutide TRIUMPH-2 results from The Lancet: up to 20.8% weight loss and a 1.6-point A1C drop in type 2 diabetes, side effects by dose, and what comes next.
PEPTIDES for Veterans Act: What the VA Peptide Bill Actually Does (2026)
Rep. Nancy Mace introduced the PEPTIDES for Veterans Act on September 1, 2026, ordering the VA to study peptide therapies and run a voluntary pilot. What the bill does, what the evidence shows, and what veterans can legally access today.
BPC-157 Statistics 2026: Trials, FDA Status, Usage & Prices (Updated September)
60+ sourced BPC-157 statistics for 2026: the 8-6-1 FDA advisory vote, every registered human trial, 232 PubMed papers, search interest, vendor prices, and what PeptideDeck's own readers ask. Every number links to its source. Updated monthly.
GLP-1 Microdosing Statistics 2026: Usage, Doses, Costs & Outcomes (Updated September)
The GLP-1 microdosing statistics that have a source behind them: how many Americans use GLP-1s, what the small trial doses actually did, side effects and dropout by dose, compounding enforcement, prices, and what PeptideDeck readers ask. Every number linked. Updated monthly.
CagriSema vs Retatrutide: Which Wins on Weight Loss in 2026?
CagriSema vs retatrutide in 2026: 22.7% vs 28.3% weight loss, why the two phase 3 trials are not comparable, and the tirzepatide bridge that settles it.
Reader discount
99%+ purity research peptides — third-party tested, COA included
Save 50% with code PEPTIDEDECK
Minoxidil for Women: 2% vs 5%, Results Timeline & Side Effects
Minoxidil for women: which strength is FDA-approved, how long results take, the shedding phase explained, side effects, and what happens when you stop.
Best Peptide Affiliate Program 2026: 10 Peptides Affiliate Programs Compared
Best peptide affiliate program for 2026: ten peptides affiliate programs compared on commission, cookie, payout speed and recurring pay, with real earnings scenarios and how to negotiate up.
FDA Peptide Vote 2026: 6 of 7 Backed for Compounding
FDA advisers backed BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax while rejecting Emideltide/DSIP. See every tally, what the non-binding recommendations mean, and what FDA does next.
Retatrutide Phase 3 Results: 22.6% Weight Loss and a 2027 FDA Filing
Eli Lilly’s latest retatrutide Phase 3 results show up to 22.6% average weight loss in TRIUMPH-3 and 20.8% in TRIUMPH-2. Here is what the topline data, cardiovascular findings, side effects, and planned Q1 2027 FDA filing mean.